Form 8-K for HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.
Results of Operations and Financial Condition, Ot
The information in this Items 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of
Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
– Describing the Company’s Cellframe � implant technology as comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells,
– that it continues to work to refine its new platform and to develop compelling data in support of its goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in late 2016,
– that based on its existing preclinical data, the Company has selected life-threatening conditions of the esophagus as the initial clinical application for advancing its Cellframe technology through the IND process, and
– that the Company currently anticipates providing an update on its ongoing large-animal research collaboration with Mayo Clinic mid-second quarter 2016.
Exhibit Number Title Press Release issued by Harvard Apparatus Regenerative Technology, Inc. on 99.1 March 17, 2016